These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27537382)

  • 41. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
    Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
    Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
    Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
    Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
    Wu Z; Ma S; Jing S; Deng Q; Zheng Z; Wu K; Li J; Chen S; Tang R; Li X
    Hepatogastroenterology; 2014 Jun; 61(132):972-7. PubMed ID: 26158151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma.
    Zhang Q; Tey J; Peng L; Yang Z; Xiong F; Jiang R; Liu T; Fu S; Lu JJ
    Radiother Oncol; 2012 Jan; 102(1):51-5. PubMed ID: 22178689
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of preoperative treatments on lymph node counts after total gastrectomy in esophagogastric adenocarcinoma.
    Li Z; Li S; Bu Z; Zhang L; Wu X; Shan F; Jia Y; Ji X; Ji J
    J Surg Oncol; 2018 Sep; 118(4):657-663. PubMed ID: 30196579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
    Kamiya T; Uehara K; Nakayama G; Ishigure K; Kobayashi S; Hiramatsu K; Nakayama H; Yamashita K; Sakamoto E; Tojima Y; Kawai S; Kodera Y; Nagino M;
    Eur J Surg Oncol; 2016 Jun; 42(6):829-35. PubMed ID: 26968228
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
    Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
    Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
    Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
    Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.
    Cienfuegos JA; Rotellar F; Baixauli J; Beorlegui C; Sola JJ; Arbea L; Pastor C; Arredondo J; Hernández-Lizoáin JL
    Ann Surg Oncol; 2015 Mar; 22(3):916-23. PubMed ID: 25190129
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of locally advanced gastric cancer with the XELOX program of neoadjuvantchemotherapy combined with laparoscopic surgery: the experience in China.
    Zheng CH; Lu J; Huang CM; Li P; Xie JW; Wang JB; Lin JX
    Hepatogastroenterology; 2014 Oct; 61(135):1876-82. PubMed ID: 25713882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer.
    Lee DJ; Sohn TS; Lim DH; Ahn HK; Park SH; Lee J; Park JO; Park YS; Lim HY; Choi DI; Kim KM; Choi MG; Noh JH; Bae JM; Kim S; Min BH; Kang WK
    Cancer Chemother Pharmacol; 2012 May; 69(5):1333-8. PubMed ID: 22311161
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.
    Fujitani K; Mano M; Hirao M; Kodama Y; Tsujinaka T
    Ann Surg Oncol; 2012 Jun; 19(6):1936-43. PubMed ID: 22187120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
    Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
    Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
    Ott K; Sendler A; Becker K; Dittler HJ; Helmberger H; Busch R; Kollmannsberger C; Siewert JR; Fink U
    Gastric Cancer; 2003; 6(3):159-67. PubMed ID: 14520529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primary rectal carcinoma in patients with stage IV resectable disease at diagnosis.
    Pasetto LM; Friso ML; Pucciarelli S; Basso U; Toppan P; Rugge M; Sinigaglia G; Nitti D; Sotti G; Monfardini S
    Anticancer Res; 2007; 27(2):1079-85. PubMed ID: 17465247
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
    Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
    Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis.
    Allen CJ; Pointer DT; Blumenthaler AN; Mehta RJ; Hoffe SE; Minsky BD; Smith GL; Blum M; Mansfield PF; Ikoma N; Das P; Ajani J; Dineen SP; Fleming JB; Badgwell BD; Pimiento JM
    Ann Surg; 2021 Oct; 274(4):544-548. PubMed ID: 34132693
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Histological complete response to neoadjuvant therapy in advanced gastric carcinoma. A case report and review of literature].
    Yan Quiroz EF; De La Cruz Mio J; Álvarez Díaz V; Agreda Castro F; Villarreal González MN
    Rev Gastroenterol Peru; 2017; 37(4):379-386. PubMed ID: 29459811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.